



Defense Health Board

Pandemic Influenza Preparedness Subpanel

Gregory A. Poland, MD
Vice-President, Defense Health Board
Chair, Select Subcommittee on PI Planning and Response



Purpose

- Brief Background and Context
- Review of DHB PI Preparedness
Recommendations
- Approval Vote



Members

- **Workgroup Members**

- **Dr. Poland** (Mayo Clinic)
- **Dr. Ennis** (University of Massachusetts Medical School)
- **Dr. Silva** (University of California, Davis)
- **Dr. Oxman** (University of California, San Diego)
- **Dr. Kaplan** (University of Minnesota)
- **Dr. Miller** (Fogarty Center, NIH)
- **Dr. Dowdle** (Emory University)
- **Dr. Gardner** (Fogarty Center, NIH)
- **Dr. Lane** (NIH)
- **Dr. Clements** (Tulane University)
- **Dr. Walker** (UTMB)



Background

- **Select Subcommittee on Pandemic Influenza Response and Preparedness – established by Dr. Winkenwerder in late 2005**
- **Goals**
 - *Assist DoD in PI planning and response*
 - *Specific issues of concern include:*
 - *Epidemiology*
 - *Response*
 - *Vaccine*
 - *Antivirals*
 - *PPE*
 - *Surveillance*



ROE

- DoD-specific
- Focus on areas within our and DoD's sphere of influence
- Focus on both immediate and future recommendations
- Focus on what's feasible



Background

- Letter of Agreement (Dec 05)
 - Advisory role only
- DoD Pandemic Planning Overview (Jan 06)
- PI Scenarios (Jul 06)
- Role of Children in PI (Jul 06)
- DoD PI Response – Specific Planning and Research Recommendations (Mar 06, Jul 07)
- Use of 1203 H5N1 vaccine (Jul 07)
- Use of PPE (Jul 07)
- Recommendations on vaccine, antivirals, convalescent plasma (Jul 07)
- Recommendations on Southern Hemisphere Vaccine (Oct 07)
- Recommendations on Convalescent Plasmatherapy (Jun 08)
- Pandemic influenza preparedness recommendations (May 09)



Specific Issues

- Anti-viral Recommendations
- Vaccine Recommendations
- DoD and Interagency Decision-making
- PI Research Recommendations
- Convalescent Plasma Recommendations
- PPE Recommendations
- Novel Flu Diagnostics Recommendations
- Antimicrobial Stockpile Recommendations
- Pneumococcal Vaccine Recommendations
- Phase I-IV Clinical Trial Recommendations



Context

- Teleconferences
- Email
- Face-to-Face Meeting 8 May 2009
 - Representatives from all DoD branches, NIH, CDC, DoD-GEIS, Health Affairs, DHHS, NVPO
 - Update current situation in regards to H1N1 pandemic
 - Review prior recommendations
 - Resulted in 20 recommendations



Specific Recommendations

- Heightened active surveillance
 - Change in severity of cases
 - Change in epi of cases
 - Change in antiviral sensitivity
 - Expanded surveillance in Mexico and Central America



Specific Recommendations

- Antivirals
 - Follow current CDC guidance for use
 - Special situations
 - Shipboard
 - Special Ops
 - Deployed forces
 - Congregated forces: Recruit Training, Service Academies
 - Concerns with one drug approach
 - Replenishment of supplies



Specific Recommendations

- Special Populations
- New consideration of populations with specific needs
 - Children
 - Morbid obesity



Specific Recommendations

- Research
 - DoD positioned to materially assist with advancing the science
 - Transmission (USAFA)
 - Antiviral efficacy and resistance
 - Surveillance (Drift)
 - Encourage DoD to actively fund and support research



Specific Recommendations

- Active Surveillance
 - Heightened alert for case severity, changes in epidemiology, etc.
 - Expand surveillance into Mexico and Central America
 - Identify resources for focused Southern Hemisphere and equatorial surveillance is a priority
 - DoD-GEIS funding is a concern in timely surveillance and response



Specific Recommendations

- Interagency Interactions
- NORTHCOM, Canadian Command, and Mexican Command interactions to be encouraged and strengthened



Specific Recommendations

- Diagnostics
 - Expand ability to diagnose A/H1N1 to more locations
 - Insure continued or expanded throughput capabilities
 - Development and dissemination of a diagnostic algorithm
 - Anticipate confusion issues this Fall with concomitant seasonal virus circulation
 - Approval of alternate diagnostic platforms should be accelerated – FDA approval



Specific Recommendations

- Respiratory Disease Research
 - DoD-internal team needed for mission-critical clinical research and vaccine trials
 - Long-term funding needed



Specific Recommendations

- Vaccine Trials
 - Assist in clinical trials of candidate H1N1 vaccines (DoD Infectious Diseases Clinical Research Program – IDCRP)
 - Enhance collaborations with NIH, BARDA



Specific Recommendations

- Vaccine Trials (reiterate October 2007 recommendations)
 - Review plan for use of vaccine
 - Consider differences in implementing 1 vs 2 dose schedules
 - Electronic record keeping
 - Insure active safety surveillance capabilities
 - Electronic data transfer and database
 - Establish reporting mechanisms
 - Panel would like to review vaccine admin priorities and plan



Specific Recommendations

- Convalescent Plasma
- Reiterate May 2008 recommendations
- Collaborations with NIH, FDA, Pharma



Specific Recommendations

- Pneumococcal vaccine
- Review and update prioritization and administration plans
- Conjugate pneumococcal vaccines in phase III trials and licensure expected in near future



Specific Recommendations

- Surge Capacity
- Ensure availability of surge capacity of essential resources
- Consider manufacturer capacity limitations (vis a vis JIT ordering)



Specific Recommendations

- Communication and Education needs
 - Providers of all levels
 - Active duty
 - Guard and Reserve components
 - Beneficiaries, retirees
 - Evaluate effectiveness of strategies



DISCUSSION